JAMA Cardiology Meta-analysis: Prasugrel the Best P2Y12 Inhibitor After PCI?
\nSource TCTMD (June 5, 2026)<\/p>\n
Key Findings (15 RCTs, n=48,904):<\/p>\n
Treatment Ranking<\/p>\n
Efficacy<\/p>\n
1.\u2060 \u2060Prasugrel
\n2.\u2060 \u2060Ticagrelor
\n3.\u2060 \u2060Clopidogrel<\/p>\n
Safety<\/p>\n
1.\u2060 \u2060Clopidogrel
\n2.\u2060 \u2060Prasugrel
\n3.\u2060 \u2060Ticagrelor<\/p>\n
Clinical Message<\/p>\n
\u2022\u2060 \u2060Supports previous findings from ISAR-REACT 5, where prasugrel outperformed ticagrelor in ACS without increased bleeding.
\n\u2022\u2060 \u2060Suggests prasugrel may offer the best efficacy\u2013safety balance after PCI, particularly in younger ACS patients without prior stroke\/TIA.
\n\u2022\u2060 \u2060Ticagrelor remains effective but was associated with:
\n* More major bleeding
\n* More intracranial hemorrhage
\n* More treatment discontinuation due to adverse events<\/p>\n
Expert Perspective<\/p>\n
Donald Cutlip, MD:<\/p>\n
\u201cPrasugrel should probably move up higher in our choice of antithrombotic therapy in acute coronary syndrome.\u201d<\/p>\n
Practical Take-Home<\/p>\n
\u2022\u2060 \u2060ACS + PCI (no prior stroke\/TIA): Prasugrel may be the preferred P2Y12 inhibitor.
\n\u2022\u2060 \u2060High bleeding risk or elderly\/frail patients: individualized selection remains essential.
\n\u2022\u2060 \u2060Clopidogrel remains the safest but least effective option.
\n\u2022\u2060 \u2060Ticagrelor continues to be guideline-recommended but may no longer be viewed as the default potent P2Y12 inhibitor when prasugrel is suitable.<\/p>\n